IntroductIon
Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease caused by deficient α-l-iduronidase (IDUA) activity that leads to the accumulation of the glycosaminoglycans (GAG) dermatan and heparan sulfate. It is the most common MPS, affecting nearly 1 in 100,000 live births. 1 In the severe Hurler syndrome, patients have umbilical hernias, skeletal deformities, joint disease, facial dysmorphia, corneal clouding, aortic dilatation, valvular heart disease, mental retardation, chronic rhinitis, recurrent middle ear infections, and liver and spleen enlargement. The attenuated Scheie syndrome has reduced systemic symptoms without neurological involvement, whereas the Hurler-Scheie syndrome is intermediate in severity. The canine model of MPS I is caused by a G to A transition in the 5′ splice site of the first intron 2, 3 and results in disease similar to that in humans. However, dogs also have thickening and prolapse of the third eyelid (membrana nictitans), as well as joint laxity instead of joint stiffness; they do not have obvious cognitive impairment, rhinitis, or middle ear infections.
MPS I is currently treated with hematopoetic stem cell transplant (HSCT) or enzyme replacement therapy (ERT). Lysosomal enzymes acquire mannose 6-phosphate (M6P) during transport through the Golgi, which allows the protein to bind to the M6P receptor and translocate to the lysosome. M6P-modified enzyme that is secreted by blood-derived cells or is injected intravenously (IV) can be taken up by cells via the M6P receptor. HSCT can reduce some clinical signs of disease, although bone, cartilage, cardiac, neurologic, and corneal manifestations were not completely corrected. [4] [5] [6] [7] [8] [9] Major disadvantages of HSCT include the need for a compatible donor, the expense, and the ~15% mortality rate. ERT has reduced hepatosplenomegaly, improved growth when given before puberty, increased mobility and manual dexterity, and reduced pulmonary and cardiac symptoms, although aortic insufficiency progressed with time. [10] [11] [12] [13] The high cost of ERT, more than US$500,000 per year for a 50 kg patient, is a major drawback for this long-term treatment.
Systemic gene therapy could program some cells to secrete IDUA, which could be taken up by other cells via the M6P receptor. Indeed, neonatal gene therapy in MPS I mice with a gamma retroviral vector (RV), 14,15 a lentiviral vector, 16 or an adeno-associated virus vector 17 resulted in stable IDUA expression and reduced clinical manifestations. Extending these studies to a large animal model such as the MPS I dog is important, as their response will probably be more predictive of results in humans. However, previous attempts at gene therapy in the MPS I dog failed to induce long-term expression of IDUA owing to www.moleculartherapy.org vol. 15 no. 8 aug. 2007
© The American Society of Gene Therapy an immune response, failure of cell engraftment, or low transduction efficiency. [18] [19] [20] [21] [22] We recently reported that neonatal IV injection of a canine IDUA-expressing gamma RV resulted in stable serum IDUA activity in MPS I dogs for up to 1.5 years without an immune response. 23 We report herein that this results in marked reductions in clinical, biochemical, and pathological manifestations of disease. results neonatal gene therapy results in stable serum IduA activity Nine MPS I dogs were injected IV at 2-3 days of age with an average dose of 4.3 ± 3.4 × 10 9 transducing units/kg of hAATcIDUA-WPRE, as summarized in Table 1 . This RV has intact long-terminal repeats (LTRs) but can also express canine IDUA from an internal liver-specific human α 1 -antitrypsin promoter.
23
All six RV-treated dogs that survived long term had stable serum IDUA activity for 1 year or longer that averaged 366 ± 344 units (U)/ml. 23 Two animals (I-99 and I-101) had relatively low serum IDUA activity at 23 and 27 U/ml, respectively (twofold normal) and will be referred to hereafter as RV-treated dogs with low serum IDUA activity. Four animals (I-107, I-140, I-171, and I-172) had average serum IDUA activity of 553, 888, 240, and 608 U/ml, respectively (overall average 535 ± 285 U/ml, 41-fold normal) and will be referred to hereafter as RV-treated dogs with high serum IDUA activity. The IDUA activity in individual dogs did not correlate well with the RV dose. Untreated MPS I dogs had very low serum IDUA activity at 0.5 ± 0.1 U/ml.
survival of rV-treated dogs
Two of nine RV-treated dogs (22%) died before 2 weeks of age. Post-mortem evaluation did not find evidence of inflammation, and the cause of these early deaths was not clear. This frequency was not significantly different from the 20% death rate in 10 untreated MPS I puppies between 2 days and 2 weeks after birth. In addition, 17% of untreated MPS I puppies that were alive at birth died within 2 days (N = 23), further suggesting that early deaths may be due to the poor viability of MPS I puppies rather than the gene therapy. Of the remaining seven RV-treated dogs, one died at 2.5 months of an unclear etiology at post-mortem and another developed a mild gait problem owing to luxation of both shoulders at 12 months and was euthanized to obtain tissue for analysis; the remaining five RV-treated dogs were alive and well at the last evaluation (at 18 months) for two dogs or at the time of euthanasia (at 21, 19, and 15 months). All untreated MPS I dogs that were alive at 2 weeks survived at least 6 months. However, of four untreated MPS I dogs that were followed for 12-21 months, two dogs (50%) developed neurological disease and were euthanized, as will be discussed further below.
clinical improvement in rV-treated MPs I dogs
The RV-treated animals showed improvements in many of the clinical signs associated with MPS I, as summarized in Table 1 . For example, all untreated MPS I dogs had umbilical hernias, but hernias were absent or had closed over time in all RV-treated dogs. Two of five untreated MPS I dogs had chest deformities characterized by a sigmoid curve of the ventral aspect of the caudal ribcage, resulting in mild flattening of the chest. Chest deformities were absent in all RV-treated MPS I dogs. Joint disease was noted in four of five untreated MPS I dogs and involved effusion, laxity, crepitus on manipulation, and/or deformity of the normal joint angle of the elbows, carpi, phalanges, and/or stifles (knees). No RV-treated dogs had clinical signs of joint disease. RV-treated dogs also showed decreased skeletal abnormalities, as will be discussed in a future publication.
Facial appearance
Untreated MPS I dogs had a characteristic depressed bridge of the nose; this resulted in a curved muzzle that was apparent at 3-6 months of age and remained abnormal thereafter, as illustrated at 1 year in Figure 1b . In contrast to MPS VII dogs, the snout length of MPS I dogs appeared relatively normal. All untreated MPS I dogs had a facial dysmorphic score of 3 (appeared severely affected) at 7 months or older (N = 5). In contrast, RV-treated dogs had a dysmorphic score of 0 (appeared normal) at all ages of evaluation, as shown for representative examples in Figure 1c and d (N = 6; P < 0.001 for MPS I versus RV-treated). Four of five untreated MPS I dogs had thickening and prolapse of the third eyelid (Figure 1f) , a triangular structure that sometimes partially covers the lower medial part of the eye and contains cartilage and a tear gland. The third eyelid was normal in all RV-treated dogs (Figure 1g and h) .
corneal clouding
Corneal clouding was scored from 0 (normal) to 3 (severe). Corneal clouding in untreated MPS I dogs resulted in a blurry view of the fundus (Figure 1j ) and an orange peel-like corneal texture due to granular opacities (Figure 1n) . Corneal clouding was scored at 2 ± 0 at both 6 and 12 months in untreated MPS I dogs (N = 4) and was markedly reduced in the RV-treated dogs regardless of the serum IDUA activity (Figure 1k , l, o and p), with scores of 0.9 ± 0.5 at 6 months (N = 5; P = 0.005) and 0.6 ± 0.5 at 12 months (N = 6; P = 0.001).
organ lysosomal enzyme and GAG levels In a previous study, liver had the highest expression after neonatal RV-mediated gene therapy to MPS VII dogs, although spleen and blood cells had 33 and 2% as much RV RNA as liver after normalization to β-actin levels. 24 Liver biopsies obtained at 4 months from RV-treated MPS I dogs had 428 ± 425 U/mg of IDUA activity, which was 15-fold the value of 27 ± 8 U/mg in normal dogs (Figure 2a) . The serum IDUA activity was directly proportional to the liver IDUA activity for individual dogs. Untreated MPS I dogs had very low liver IDUA activity at 1.1 ± 0.2 U/mg.
Organs from post-mortem samples were evaluated for IDUA activity for two RV-treated dogs with low serum IDUA activity (I-99 and I-101) and two RV-treated dogs with high serum IDUA activity (I-107 and I-140), and white blood cells (WBCs) were analyzed from two RV-treated dogs with high serum IDUA activity (I-171 and I-172) . Liver IDUA activity remained high at 300 ± 384 U/mg (Figure 2a) . The percentage normal IDUA activity in RV-treated dogs was 1,000% in spleen, 80% in brain, 30% in heart, 230% in kidney medulla, 210% in kidney cortex, 20% in aorta, and 56% in WBC. MPS I results in an elevation © The American Society of Gene Therapy of other lysosomal enzymes, and correction of disease normalizes these values. Organs of untreated MPS I dogs had total β-hexosaminidase levels 2.1-to 4.6-fold the levels in normal dogs (P < 0.01, Figure 2b) , although values in WBC were only 1.3-fold normal. The RV-treated dogs had β-hexosaminidase levels 1.0-to 1.9-fold normal, which were lower (P < 0.05) than values in untreated MPS I dogs in all sites except WBC. MPS I results in accumulation of soluble sulfated GAGs, and correction of disease normalizes these values. Untreated MPS I dogs had organ GAG levels that were 17-to 108-fold normal (Figure 2c ; P < 0.01), although values in WBC were only fourfold normal. GAG levels were reduced to 1.0-to 2.6-fold normal in RV-treated dogs (not significant versus normal), which was significantly lower than values in untreated MPS I dogs (P < 0.01) in all sites except WBC. Figure 3a shows representative images of echocardiograms obtained at 1 year, and Figure 3b shows average scores for echocardiogram-derived parameters at 6 and 12 months. Untreated MPS I dogs had mild aortic dilatation, with a diameter of 40.1 ± 9.8 mm/m 2 body surface area at 12 months. At this age, RV-treated dogs had an average aorta diameter of 24.5 ± 4 mm/m 2 (P = 0.003 versus untreated MPS I dogs), which was similar to values in normal dogs (not shown). At 12 months, untreated MPS I dogs had a mild subjective aortic dilatation score of 1.0 ± 0.8 on a scale of 0 (normal) to 4 (severely abnormal), which was significantly higher than the value of 0 ± 0 (P = 0.015) in RV-treated dogs. Aortic valve thickening and aortic insufficiency were mild, and there were no significant differences between the groups at 12 months.
Heart
There were moderate amounts of lysosomal storage (severity score 2.0 ± 0 on a scale from 0 (normal) to 3 (severe)) and mild elastic fiber fragmentation (severity score on the same scale of 1.8 ± 0.5) throughout the layers of the media of the aortas from untreated MPS I dogs (Figure 3c ). Aortas from three of four RV-treated dogs appeared completely normal, whereas the aorta from one RV-treated dog with low serum IDUA activity (I-101) had mild (score = 1) storage and elastin fragmentation in 
Normal dogs
Average ± SD 13.0 ± 1.9 N = 6
Abbreviations: MPS I, mucopolysaccharidosis I, RV, retroviral vector; IDUA, α-l-iduronidase. a At time of death or current age at time of writing (I-171 and I-172) in months except for I-108, where values are given in days. © The American Society of Gene Therapy the middle region of the aortic media. This resulted in an overall score of 0.25 ± 0.5 for both of these parameters in RV-treated dogs, which was significantly lower (P < 0.01) than in untreated MPS I dogs. Mitral valve thickening analysis is shown in the bottom panels of Figure 3a and is quantified in Figure 3b . Untreated MPS I dogs had moderate mitral valve leaflet thickening, with severity scores of 1.6 ± 0.5 and 1.5 ± 0.6 at 6 and 12 months, respectively. Mitral valve thickening scores were markedly reduced in the RVtreated dogs at 0.5 ± 0.6 (P = 0.009) and 0.3 ± 0.5 (P = 0.01) at 6 and 12 months, respectively. Mild mitral valve insufficiency was present in both groups and also in some normal controls, and there were no significant differences between untreated and RVtreated MPS I dogs.
neurological disease
Cognitive impairment was not obvious in untreated MPS I dogs: they displayed normal canine behavior, chased balls, and responded to their names. Human patients can have spinal cord compression from bone and vertebral disc disease or thickening of the meninges. Indeed, one untreated MPS I dog (I-113) with narrowing of the C5/C6 intervertebral disc space on radiographs (data not shown) was quadraparetic and had proprioceptive deficits and hyperreflexia in all four limbs at 14 months. A second dog (I-119) showed pelvic limb proprioceptive deficits and hyperreflexia, suggesting spinal cord disease between T3 and L3, although disc space narrowing was not noted on radiographs. Both dogs were euthanized for humane reasons at the onset of these signs. Signs of spinal cord disease were absent in the RV-treated MPS I dogs. In addition, the untreated MPS I dog I-119 developed nystagmus and ataxia of the head and limbs at 12 months, suggesting cerebellar and/or vestibular system involvement. Ataxia was not seen in any RV-treated dogs.
Pathology of the brain
Brains were evaluated histologically for evidence of lysosomal storage. All untreated MPS I dogs had numerous large dark granules in most cortical neurons when 1-µm sections were stained with toludine blue (Figures 4b and f) Electron microscopy confirmed that the dark granules in (Figure 4j ) or large lysosomes with circular whorls (not shown), which have previously been reported to represent lysosomal storage in patients with MPS I. 1 All RV-treated MPS I dogs had a remarkable reduction in the amount of lysosomal storage in the cortical neurons as assessed with light microscopy regardless of the serum IDUA activity. In addition, zebra bodies and large lysosomes with circular whorls were absent when electron microscopy was performed on brain cortex from one RV-treated dog with low and one with high serum IDUA activity. However, the dog with low serum IDUA activity did have occasional cells with increased numbers of small lysosomes (Figure 4k) , which may represent modest amounts of lysosomal storage. Untreated MPS I dogs had five or more granules that were consistent with lysosomal storage in 79 ± 9% of cortical neurons (Figure 4q) , which was significantly higher (P < 0.01) than the percentage of cells with granules in normal (14 ± 3%) or RV-treated (11 ± 8%) dogs. Similarly, untreated MPS I dogs had vacuoles consistent with lysosomal storage in 98 ± 4% of Purkinje cells (Figure 4n and r) . This was significantly higher (P < 0.01) than the values of 14 ± 6% in normal dogs and of 17 ± 12% in Note the normal narrowing at the right side of the aorta in the normal and both RV-treated MPS I dogs, which was absent in the untreated MPS I dog. The bottom panels show the left atrium (LA), mitral valve apparatus, and LV. The insertion of normal chordae tendinae (CT) into the mitral valve leaflets is indicated with white arrowheads. In the untreated MPS I dog, the chordae tendinae and tips of the mitral valve leaflets are thickened and nodular, as indicated by the long white arrow. Scale bar = 1 cm. (b) Quantification of the echocardiograms. Echocardiograms were performed at 6 and 12 months after birth on four untreated MPS I and six RV-treated MPS I dogs. In the left panel, the long-axis diameter of the aorta was normalized to the body surface area in square meters (m 2 ), and the mean ± SD determined. Values in the two groups were compared with the Student's t-test; * indicates a P value of 0.01-0.05, and ** indicates a P value <0.01. In the other panels, the parameter was scored from 0 (normal) to severely abnormal (4), and the average scores were determined and compared statistically. (c) Pathology of the aorta. Aortas were collected at the age indicated above the panels and then stained for elastin. Lysosomal storage is identified with black arrowheads, and fragmentation of the elastin fibers is identified with long black arrows. Scale bar = 240 µm for the top panels and 60 µm for the bottom panels. AI, aortic insufficiency; AV, aortic value; MI, mitral insufficiency; MV, mitral value; thick, thickening. which were absent in all RV-treated dogs (data not shown).
Mitral valve

Vector dnA and rnA in liver, blood cells, and brain
The RV DNA copy number was evaluated in liver using real-time polymerase chain reaction (real-time PCR) for the woodchuck hepatitis post-transcriptional regulatory element (WPRE) of the RV with normalization to β-actin levels (Figure 5a) . Livers from RV-treated dogs with low and high serum IDUA activity had 0.11 ± 0.02 and 3.2 ± 1.5 copies of RV per 100 cells, respectively. This suggests that the 21-fold differences in serum IDUA activity between the two groups may be due to the 29-fold variation in liver transduction efficiency. RV DNA was present at low levels in WBC of RV-treated dogs with high serum IDUA activity but was not analyzed in RV-treated dogs with low serum IDUA activity. Similarly, RV DNA was present at low levels in brain of RV-treated dogs with low and high serum IDUA activity. However, it was not possible to quantify the amount of DNA in either WBC or brain because the C T for the WPRE was high (35-38), which is a level where the standard curve is not linear in our hands. The DNA concentration was estimated to be less than 0.1 copy per 100 cells in both organs. WBC and brain from non-transduced MPS I or normal dogs had WPRE C T values of 40, demonstrating the specificity of the real-time PCR for RV sequences (data not shown). RNA was evaluated with IDUA primers that amplified the endogenous as well as the RV-derived canine IDUA complementary DNA (cDNA), with WPRE primers specific for the RVderived RNA, and with β-actin primers for normalization. The liver IDUA signal in normal and MPS I dogs was, respectively, 5.6 ± 0.4% and 22 ± 5% of the β-actin signal (Figure 5b) , demonstrating that untreated MPS I dogs had fourfold more IDUA RNA in liver than normal dogs. As expected, the liver WPRE signal was undetectable in both normal and untreated MPS I dogs. RV-treated dogs with low serum IDUA activity had 67% of normal liver IDUA RNA levels, which was less than the background in untreated MPS I dogs. However, the liver WPRE RNA was 7.4 ± 4.0% of β-actin, indicating that IDUA expression was 132% of normal-assuming that the IDUA and the WPRE primer sets amplified equally well. This was consistent with the liver IDUA activity of 110% of normal in these RV-treated dogs with low serum IDUA activity. RV-treated dogs with high serum IDUA activity had IDUA RNA levels that were 135 ± 78% of β-actin (24-fold normal) and WPRE RNA levels that were 323 ± 277% of β-actin (58-fold normal, assuming the IDUA and WPRE primers amplified equally well). The RNA levels in RV-treated dogs with high serum IDUA activity were consistent with liver IDUA activity that was 32-fold normal.
RNA was also evaluated from WBC (Figure 5c ) and cerebral cortex (Figure 5d ) to determine whether RV expression in these sites might have contributed to the correction of lysosomal storage in RV-treated dogs. MPS I dog WBC and brain had 74 and 142% as much IDUA RNA as in normal dogs, respectively, and did not have a signal for the WPRE. The WPRE signal in WBC of RVtreated dogs with high serum IDUA activity was 0.02 ± 0.02% of β-actin, which was 6% of the level in normal WBC if one assumes that the WPRE and IDUA primers amplify equally well. WBC RNA was not evaluated in RV-treated dogs with low serum IDUA activity. The WPRE signal in brain of RV-treated dogs with low or high serum IDUA activity was 0.2 ± 0.002 or 0.5 ± 0.5% of β-actin, respectively. This indicates that RV-treated dogs with low or high serum IDUA activity had 10 or 24% as much IDUA RNA in brain, respectively, as normal dogs if the IDUA and WPRE primers amplified equally well.
dIscussIon
This study demonstrates that many clinical manifestations were prevented in MPS I dogs that achieved stable IDUA expression after neonatal IV injection of an RV. The RV-treated dogs with low and high serum IDUA activity had 25 ± 3 U/ml (2-fold normal) and 535 ± 285 U/ml (41-fold normal) of IDUA activity in serum, respectively. The major source of enzyme in blood was probably the liver, which we previously demonstrated was the organ with the highest expression after a similar gene therapy approach in MPS VII dogs. 24 The lack of overt adverse effects from very high serum IDUA activity is likely due to the fact that IDUA functions best at a low pH and acts only upon terminal iduronic acids in GAG chains. 28 Serum from these RV-treated dogs did not have anti-canine IDUA immunoglobulin G antibodies in an enzyme-linked immunosorbent assay in which wells that were coated with canine IDUA were used to capture antibodies (data not shown). This was somewhat surprising given that MPS I dogs mounted an antibody response to canine IDUA protein after ERT 29 and to canine IDUA after HSC-or myoblast-directed gene therapy. [18] [19] [20] The immaturity of the immune response at birth may have contributed to this failure to produce anti-canine IDUA antibodies. Alternatively, the lack of antibodies could be due to the high serum levels of canine IDUA, as animals with 25 U/ml have ~100 ng/ml or ~2 nmol/l of serum canine IDUA, assuming a specific activity of 250,000 U/mg. 30 This concentration was effective at preventing an antibody response to human Factor IX after neonatal gene therapy.
31
The stable expression in RV-treated dogs indicates indirectly that a cytotoxic T-lymphocyte response did not destroy transduced cells. This result differs from that in MPS I cats that received the same canine IDUA-expressing RV as newborns and mounted a potent cytotoxic T-lymphocyte response.
23 Although we previously hypothesized that the newborn immune system may be less mature in dogs than in cats, it is also possible that MPS I dogs express canine IDUA epitopes and develop tolerance. Indeed, IDUA messenger RNA was near-normal in untreated MPS I dogs in this study, and substantial amounts of an IDUA cDNA were amplified from blood cells of untreated MPS I dogs with exon 3 and exon 6 primers in a previous study. 20 The finding of near-normal levels of IDUA RNA in untreated MPS I dogs in this study differs from the result in fibroblasts from MPS I dogs, where levels of a 2.8 kilobase RNA (which was hypothesized to include the 450 bp intron 1 and sequences from the wild-type 2.2 kilobase messenger RNA) were both low.
2,3 The 5′ splice site mutation results in a stop codon within intron 1 at nucleotide 519 (GI:163964) and a truncated 52 amino acid protein, yet translational initiation at the second AUG at nucleotide 942 within intron 1 would be in frame with exon 2 (starts at nucleotide 968) and would produce a protein with MPAPSLCPS in addition to the sequence encoded by exons 2-14. This putative protein lacks a signal sequence and should not be secreted or transported to the lysosome, but it could result in epitope presentation and tolerance. Although it was previously proposed that ex vivo gene therapy of HSC 19, 20 or myoblasts 18 may have resulted in a cytotoxic T-lymphocyte response to canine IDUA, these data were indirect. Further studies with the human IDUA gene in the MPS I dogs may help to determine whether the prolonged expression observed in this study was due to the immaturity of the newborn canine immune system or to tolerance to canine IDUA epitopes.
Heart disease
Cardiac disease can result from storage in heart values, aorta, coronary arteries, and/or myocardium. In this study, untreated MPS I dogs had moderate thickening of the mitral valve, which was markedly reduced in all RV-treated dogs regardless of the serum IDUA activity. Similarly, heart valve thickening stabilized or was reduced after HSCT or ERT. Untreated MPS I dogs had aortic diameters that were mildly dilated at 164% of normal at 1-1.5 years of age, which was associated with moderate amounts of lysosomal storage and mild elastic fiber fragmentation throughout the thickness of the media. Pathology in dogs was similar to that in untreated humans but less severe than in MPS I mice. 14, [32] [33] [34] This difference in severity may result from less lysosomal storage per cell in the aorta of large animals than in mice. Both RV-treated dogs with high serum IDUA activity (553 and 888 U/ml) had complete correction of aortic disease, which was consistent with the ability of neonatal gene therapy to correct aortic disease in mice if serum IDUA activity is >500 U/ml. 14 Although one RV-treated dog with low serum IDUA activity (23 U/ml) that was killed at 13 months had complete pathological correction in the aorta, the other RV-treated dog with low serum IDUA activity (27 U/ml; I-101) that was euthanized at 21 months had mild lysosomal storage and elastic fiber fragmentation in the middle regions of the media. The failure to prevent aortic disease in I-101 is consistent with the results in MPS I mice, where administration of a low dose of RV to neonatal mice resulted in only ~30 U/ml of serum IDUA activity.
14 Difficulties in preventing aortic disease were also encountered with other treatments: aortic regurgitation developed de novo in eight of nine patients at 12 years after performing HSCT at a mean age of 2 years; 7 and 60% of patients analyzed at 4-6 years after initiation of ERT had de novo development or worsening of aortic insufficiency.
11,13 Evaluating aortas from additional dogs with low and high serum IDUA activity at older ages will be important.
neurological disease
A major problem in children with Hurler syndrome is mental retardation, which is likely due in part to neuronal lysosomal storage. In this study, all RV-treated dogs had marked reductions in lysosomal storage in cortical neurons even when serum IDUA activity was only ~25 U/ml. This differed from the result in MPS I mice, where animals with ~30 U/ml after low-dose neonatal gene therapy had substantial lysosomal storage in neurons.
15 One difference may be that the brain of RV-treated MPS I dogs with low serum IDUA activity had 10% as much IDUA messenger RNA as did normal dog brain; this was much higher than the level of RV RNA found in brain in MPS I mice with low serum IDUA activity. Expression in brain of RV-treated dogs presumably derived from the LTR, which can drive expression of a translatable protein in non-hepatic cells.
The presence of relatively high levels of RV RNA sequences in the brain of RV-treated MPS I dogs at 1 year could be due either to transduction of brain at the time of IV injection of vector or to transduction of hematopoietic cells that migrated into brain. Analysis of DNA was not helpful at differentiating between these possibilities, because the signal was too low in both WBC and brain of RV-transduced dogs for meaningful quantitation. That RV RNA in brain was as high or higher as in WBC in this study could suggest that brain cells were transduced, but it is also possible that the LTR was up-regulated in blood-derived cells in brain. We similarly reported that DNA was present in the brain of MPS VII dogs at 6 months after neonatal gene therapy, 
